Low dose nivolumab in metastatic mucosal melanoma: a case report

被引：0

作者：

Meraz-Brenez, Andres ^{[1
]}

Navarrete-Reyes, Ana P. ^{[2
]}

Ignacio-Alvarez, Eleazar ^{[3
]}

Ramirez-Anguiano, Georgina J. ^{[4
]}

Verduzco-Aguirre, Haydee C. ^{[1
]}

机构：

[1] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Hematooncol, Mexico City, DF, Mexico

[2] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Geriatr Serv, Mexico City, DF, Mexico

[3] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Nucl Med Serv, Mexico City, DF, Mexico

[4] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Otorhinolaryngol Serv, Mexico City, DF, Mexico

来源：

GACETA MEXICANA DE ONCOLOGIA | 2023年 / 22卷 / 03期

关键词：

Melanoma; Nivolumab; Geriatric oncology; Case report; Financial toxicity; FINANCIAL TOXICITY; CANCER; POPULATION; OUTCOMES;

D O I：

10.24875/j.gamo.23000030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We present the case of a 77-year-old man with metastatic mucosal melanoma, unable to afford standard doses of immunotherapy, who was treated with nivolumab at a lower dose of 0.5 mg/kg every 2 weeks. Drug activity was demonstrated through both objective tumor response and an immune-related adverse event. This suggests that a lower dose of nivolumab could be a viable alternative for patients with advanced mucosal melanoma at a high risk of treatment-related financial toxicity. Further research is needed to evaluate the efficacy of lower doses of immunotherapy, including its impact on long term outcomes.

引用

页码：140 / 145

页数：6

共 50 条

[21] Haemorrhagic shock secondary to a diffuse ulcerative enteritis after Ipilimumab and Nivolumab treatment for metastatic melanoma: a case report
Trystram, Noemie
Laly, Pauline
Bertheau, Philippe
Baroudjian, Barouyr
Aparicio, Thomas
Gornet, Jean-Marc
ANNALS OF PALLIATIVE MEDICINE, 2022, 11 (02) : 837 - 842
[22] Nivolumab in metastatic melanoma: good efficacy and tolerability in elderly patients
De Luca, R.
Meraviglia, S.
Blasi, L.
Maiorana, A.
Cicero, G.
CURRENT ONCOLOGY, 2020, 27 (02) : E75 - E80
[23] A case report of metastatic melanoma in the popliteal fossa
Catania, Sarah
Dimech, Anthony Pio
Cassar, Kevin
INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, 2020, 77 : 885 - 889
[24] Neoadjuvant ipilimumab plus nivolumab therapy as a potential organ preservation strategy in mucosal melanoma: case report
Ong, Claire
Samlowski, Wolfram
FRONTIERS IN ONCOLOGY, 2024, 14
[25] Myosteatosis is prognostic in metastatic melanoma treated with nivolumab
Youn, Susie
Reif, Rebecca
Chu, Michael P.
Smylie, Michael
Walker, John
Eurich, Dean T.
Ghosh, Sunita
Sawyer, Michael B.
CLINICAL NUTRITION ESPEN, 2021, 42 : 348 - 353
[26] Fecal transplantation in patient with metastatic melanoma refractory to immunotherapy: A case report
del Giglio, Auro
Atui, Fabio Cesar
WORLD JOURNAL OF CLINICAL CASES, 2023, 11 (24) : 5830 - 5834
[27] A case report of using nivolumab for a malignant melanoma patient with rheumatoid arthritis
Kageyama, Shun-Ichiro
Yamaguchi, Shigeo
Ito, Shin
Suehara, Yoshiyuki
Saito, Tsuyoshi
Akaike, Keisuke
Miura, Kayo
Kato, Shunsuke
INTERNATIONAL CANCER CONFERENCE JOURNAL, 2016, 5 (04): : 192 - 196
[28] Pseudo-Progression of Melanoma Treated with Nivolumab/Ipilimumab: A Case Report
Velazquez, Adan Martin Cuevas
Ng, Wern Lynn
Martinez, Evelyn J. Calderon
Yeruva, Sri Lakshmi Hyndavi
AMERICAN JOURNAL OF CASE REPORTS, 2023, 24
[29] A case report of using nivolumab for a malignant melanoma patient with rheumatoid arthritis
Shun-Ichiro Kageyama
Shigeo Yamaguchi
Shin Ito
Yoshiyuki Suehara
Tsuyoshi Saito
Keisuke Akaike
Kayo Miura
Shunsuke Kato
International Cancer Conference Journal, 2016, 5 (4) : 192 - 196
[30] Case Report: Durable complete pathologic response and organ preservation following ipilimumab and nivolumab for locally advanced primary vaginal mucosal melanoma
Tarhini, Ahmad A.
Hanayneh, Wissam B.
Powers, John J.
Segura, Carlos M. Moran
Conejo-Garcia, Jose R.
Lam, Cesar A.
Hakam, Ardeshir
Hoffman, Mitchel S.
FRONTIERS IN ONCOLOGY, 2022, 12

← 1 2 3 4 5 →